Biological rationales and clinical applications of temperature controlled hyperthermia - implications for multimodal cancer treatments

Current Medicinal Chemistry

Volumn 17, Issue 27, 2010, Pages 3045-3057

  Schildkopf, P ^a   Ott, O J ^a   Frey, B ^a   Wadepohl, M ^b   Sauer, R ^a,c   Fietkau, R ^a   Gaipl, U S ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Dr Sennewald Medizintechnik   (Germany)

^c United Cancer Center   (Germany)

Author keywords

Anti tumor immunity; Cancer; Chemotherapeutics; Danger signals; Hyperthermia; Immunogenic cell death; Magnetic resonance images; Radiotherapy

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MITOMYCIN; MITOXANTRONE; OXALIPLATIN; TEMOZOLOMIDE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CELL DEATH; CHEMOSENSITIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOTOXICITY; DRUG ACTIVITY; HEAT TOLERANCE; HUMAN; HYPERTHERMIC THERAPY; IMMUNOMODULATION; IONIZING RADIATION; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SOFT TISSUE SARCOMA; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; HYPERTHERMIA, INDUCED; NEOPLASMS;

EID: 77955622857     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791959774     Document Type: Article

References (167)

1. Hildebrandt, B.; Wust, P.; Ahlers, O.; Dieing, A.; Sreenivasa, G.; Kerner, T.; Felix, R.; Riess, H. The cellular and molecular basis of hyperthermia. Crit. Rev. Oncol. Hematol., 2002, 43, 33-56.
2. Dewey, W.C. Arrhenius relationships from the molecule and cell to the clinic. Int. J. Hyperthermia, 1994, 10, 457-483.
3. Dewhirst, M.W.; Prosnitz, L.; Thrall, D.; Prescott, D.; Clegg, S.; Charles, C.; MacFall, J.; Rosner, G.; Samulski, T.; Gillette, E.; LaRue, S. Hyperthermic treatment of malignant diseases: current status and a view toward the future. Semin. Oncol., 1997, 24, 616- 625.
4. Urano, M.; Kuroda, M.; Nishimura, Y. For the clinical application of thermochemotherapy given at mild temperatures. Int. J. Hyperthermia, 1999, 15, 79-107.
5. Dewey, W.C.; Thrall, D.E.; Gillette, E.L. Hyperthermia and radiation--a selective thermal effect on chronically hypoxic tumor cells in vivo. Int. J. Radiat. Oncol. Biol. Phys., 1977, 2, 99-103.
6. Westra, A.; Dewey, W.C. Variation in sensitivity to heat shock during the cell-cycle of Chinese hamster cells in vitro. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med., 1971, 19, 467-477.
7. Henle, K.J. Arrhenius analysis of thermal responses. Hall: Boston 1983.
8. Overgaard, J.; Suit, H.D. Time-temperature relationship th hyperthermic treatment of malignant and normal tissue in vivo. Cancer Res., 1979, 39, 3248-3253.
9. Sapareto, S.A.; Raaphorst, G.P.; Dewey, W.C. Cell killing and the sequencing of hyperthermia and radiation. Int. J. Radiat. Oncol. Biol. Phys., 1979, 5, 343-347.
10. Issels, R.D. Hyperthermia adds to chemotherapy. Eur. J. Cancer, 2008, 44, 2546-2554.
11. Vaupel, P.; Kallinowski, F.; Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res., 1989, 49, 6449-6465.
12. Vaupel, P.; Mayer, A.; Hockel, M. Tumor hypoxia and malignant progression. Methods Enzymol., 2004, 381, 335-354.
13. Steel, G.G. From targets to genes: a brief history of radiosensitivity. Phys. Med. Biol., 1996, 41, 205-222.
14. Ward, J.F. Radiation mutagenesis: the initial DNA lesions responsible. Radiat. Res., 1995, 142, 362-368.
15. Goodhead, D.T. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int. J. Radiat. Biol., 1994, 65, 7-17.
16. Hall, E.J. Radiobiology for the radiologist. 5 ed. Philadelphia: Lippincott Williams & Wilkins, 2000.
17. Willers, H.; Held, K.D. Introduction to clinical radiation biology. Hematol. Oncol. Clin. North. Am., 2006, 20, 1-24.
18. Ward, J.F. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog. Nucleic. Acid. Res. Mol. Biol., 1988, 35, 95-125.
19. Goodhead, D.T.; Thacker, J.; Cox, R. Weiss Lecture. Effects of radiations of different qualities on cells: molecular mechanisms of damage and repair. Int. J. Radiat. Biol., 1993, 63, 543-556.
20. Willers, H.; Heilmann, H.P.; Beck-Bornholdt, H.P. [One hundred years of radiotherapy. Historical origins and development of fractionated irradiation in German speaking countries]. Strahlenther. Onkol., 1998, 174, 53-63.
21. Taneja, N.; Tjalkens, R.; Philbert, M.A.; Rehemtulla, A. Irradiation of mitochondria initiates apoptosis in a cell free system. Oncogene, 2001, 20, 167-177.
22. Schildkopf, P.; Frey, B.; Mantel, F.; Ott, O.J.; Weiss, E.M.; Sieber, R.; Janko, C.; Sauer, R.; Fietkau, R.; Gaipl, U.S. Application of hyperthermia in addition to ionizing irradiation fosters necrotic cell death and HMGB1 release of colorectal tumor cells. Biochem. Biophys. Res. Commun., 2010, 391, 1014-20.
23. Schildkopf, P.; Holmer, R.; Sieber, R.; Ott, O.J.; Janko, C.; Mantel, F.; Frey, B.; Fietkau, R.; Gaipl, U.S. Hyperthermia in combination with X-irradiation induces inflammatory forms of cell death. Autoimmunity, 2009, 42, 311-313.
24. Suit, H.D.; Westgate, S.J. Impact of improved local control on survival. Int. J. Radiat. Oncol. Biol. Phys., 1986, 12, 453-458.
25. Cepeda, V.; Fuertes, M.A.; Castilla, J.; Alonso, C.; Quevedo, C.; Perez, J.M. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med. Chem., 2007, 7, 3-18.
26. Montecucco, A.; Biamonti, G. Cellular response to etoposide treatment. Cancer Lett., 2007, 252, 9-18.
27. Rixe, O.; Fojo, T. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin. Cancer Res., 2007, 13, 7280-7287.
28. Kufe D.W.; E. P.R.; Weichselbaum R.R.; Bast, R.C.; Gansler, T.S.; Holland, J.F.; Frei, E. Cancer Medicine. 6 ed. BC, Decker Inc.: Hamilton, 2003.
29. Hurley, L.H. DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer, 2002, 2, 188-200.
30. Chaney, S.G.; Sancar, A. DNA repair: enzymatic mechanisms and relevance to drug response. J. Natl. Cancer Inst., 1996, 88, 1346-1360.
31. Drablos, F.; Feyzi, E.; Aas, P.A.; Vaagbo, C.B.; Kavli, B.; Bratlie, M.S.; Pena-Diaz, J.; Otterlei, M.; Slupphaug, G.; Krokan, H.E. Alkylation damage in DNA and RNA--repair mechanisms and medical significance. DNA Repair (Amst.), 2004, 3, 1389-1407.
32. Margison, G.P.; Santibanez-Koref, M.F. O6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. Bioessays, 2002, 24, 255-266.
33. Memisoglu, A.; Samson, L. Contribution of base excision repair, nucleotide excision repair, and DNA recombination to alkylation resistance of the fission yeast Schizosaccharomyces pombe. J. Bacteriol., 2000, 182, 2104-2112.
34. Alama, A.; Tasso, B.; Novelli, F.; Sparatore, F. Organometallic compounds in oncology: implications of novel organotins as antitumor agents. Drug Discov. Today, 2009, 14, 500-508.
35. Ho, Y.P.; Au-Yeung, S.C.; To, K.K. Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med. Res. Rev., 2003, 23, 633-655.
36. Schaefer, S.D.; Post, J.D.; Close, L.G.; Wright, C.G. Ototoxicity of low- and moderate-dose cisplatin. Cancer, 1985, 56, 1934-1939.
37. Goren, M.P.; Wright, R.K.; Horowitz, M.E. Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother. Pharmacol., 1986, 18, 69-73.
38. Alberts, D.S.; Noel, J.K. Cisplatin-associated neurotoxicity: can it be prevented? Anticancer Drugs, 1995, 6, 369-383.
39. Kelland, L. The resurgence of platinum-based cancer hemotherapy. Nat. Rev. Cancer, 2007, 7, 573-584.
40. Simonian, P.L.; Grillot, D.A.; Nunez, G. Bcl-2 and Bcl-XL can ifferentially block chemotherapy-induced cell death. Blood, 1997, 0, 1208-1216.
41. Eastman, A. The mechanism of action of cisplatin: From adducts to apoptosis. Wiley-VCH: Basel, 1999.
42. Simunek, T.; Sterba, M.; Popelova, O.; Adamcova, M.; Hrdina, R.; Gersl, V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep., 2009, 61, 154-171.
43. Rayson, D.; Richel, D.; Chia, S.; Jackisch, C.; van der Vegt, S.; Suter, T. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann. Oncol., 2008, 19, 1530-1539.
44. Binaschi, M.; Bigioni, M.; Cipollone, A.; Rossi, C.; Goso, C.; Maggi, C.A.; Capranico, G.; Animati, F. Anthracyclines: selected new developments. Curr. Med. Chem. Anticancer Agents, 2001, 1, 113-130.
45. Ruiz-Ruiz, C.; Robledo, G.; Cano, E.; Redondo, J.M.; Lopez-Rivas, A. Characterization of p53-mediated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumor cells. J. Biol. Chem., 2003, 278, 31667-31675.
46. Dewhirst, M.W.; Ozimek, E.J.; Gross, J.; Cetas, T.C. Will hyperthermia conquer the elusive hypoxic cell? Implications of heat effects on tumor and normal-tissue microcirculation. Radiology, 1980, 137, 811-817.
47. Sapareto, S.A. Thermal isoeffect dose: addressing the problem of thermotolerance. Int. J. Hyperthermia, 1987, 3, 297-305.
48. Kim, S.H.; Kim, J.H.; Hahn, E.W. The enhanced killing of irradiated HeLa cells in synchronous culture by hyperthermia. Radiat. Res., 1976, 66, 337-345.
49. Mills, M.D.; Meyn, R.E. Hyperthermic potentiation of unrejoined DNA strand breaks following irradiation. Radiat. Res., 1983, 95, 327-338.
50. Schlag, H.; Lucke-Huhle, C. Cytokinetic studies on the effect of hyperthermia on Chinese hamster lung cells. Eur. J. Cancer, 1976, 12, 827-831.
51. Nordsmark, M.; Overgaard, M.; Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol., 1996, 41, 31-39.
52. Nordsmark, M.; Bentzen, S.M.; Rudat, V.; Brizel, D.; Lartigau, E.; Stadler, P.; Becker, A.; Adam, M.; Molls, M.; Dunst, J.; Terris, D.J.; Overgaard, J. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother. Oncol., 2005, 77, 18-24.
53. Hockel, M.; Schlenger, K.; Aral, B.; Mitze, M.; Schaffer, U.; Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res., 1996, 56, 4509-4515.
54. Brizel, D.M.; Sibley, G.S.; Prosnitz, L.R.; Scher, R.L.; Dewhirst, M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys., 1997, 38, 285-289.
55. Fyles, A.W.; Milosevic, M.; Wong, R.; Kavanagh, M.C.; Pintilie, M.; Sun, A.; Chapman, W.; Levin, W.; Manchul, L.; Keane, T.J.; Hill, R.P. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol., 1998, 48, 149-156.
56. Brown, J.M.; Wilson, W.R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer, 2004, 4, 437-447.
57. Streffer, C.; van Beuningen, D.; Devi, P.U. Radiosensitization by hyperthermia in human melanoma cells: single and fractionated treatments. Cancer Treat. Rev., 1984, 11 Suppl A, 179-185.
58. Dewhirst, M.W.; Vujaskovic, Z.; Jones, E.; Thrall, D. Re-setting the biologic rationale for thermal therapy. Int. J. Hyperthermia, 2005, 21, 779-790.
59. Coss, R.A.; Dewey, W.C.; Bamburg, J.R. Effects of hyperthermia on dividing Chinese hamster ovary cells and on microtubules in vitro. Cancer Res., 1982, 42, 1059-1071.
60. Dewey, W.C. Failla memorial lecture. The search for critical cellular targets damaged by heat. Radiat. Res., 1989, 120, 191-204.
61. Vidair, C.A.; Dewey, W.C. Two distinct modes of hyperthermic cell death. Radiat. Res., 1988, 116, 157-171.
62. Roti Roti, J.L. Heat-induced alterations of nuclear protein associations and their effects on DNA repair and replication. Int. J. Hyperthermia, 2007, 23, 3-15.
63. Lepock, J.R. Role of nuclear protein denaturation and aggregation in thermal radiosensitization. Int. J. Hyperthermia, 2004, 20, 115-130.
64. Iliakis, G.; Wu, W.; Wang, M. DNA double strand break repair inhibition as a cause of heat radiosensitization: re-evaluation considering backup pathways of NHEJ. Int. J. Hyperthermia, 2008, 24, 17-29.
65. Horsman, M.R.; Overgaard, J. Hyperthermia: a potent enhancer of radiotherapy. Clin. Oncol. (R. Coll. Radiol.), 2007, 19, 418-426.
66. Song, C.W.; Park, H.J.; Lee, C.K.; Griffin, R. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int. J. Hyperthermia, 2005, 21, 761-767.
67. Gellermann, J.; Hildebrandt, B.; Issels, R.; Ganter, H.; Wlodarczyk, W.; Budach, V.; Felix, R.; Tunn, P.U.; Reichardt, P.; Wust, P. Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry. Cancer, 2006, 107, 1373-1382.
68. Jain, R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 2005, 307, 58-62.
69. Van Bree, C.; Beumer, C.; Rodermond, H.M.; Haveman, J.; Bakker, P.J. Effectiveness of 2',2'difluorodeoxycytidine (Gemcitabine) combined with hyperthermia in rat R-1 rhabdomyosarcoma in vitro and in vivo. Int. J. Hyperthermia, 1999, 15, 549-556.
70. Haveman, J.; Rietbroek, R.C.; Geerdink, A.; Van Rijn, J.; Bakker, P.J. Effect of hyperthermia on the cytotoxicity of 2',2'-difluorodeoxycytidine (gemcitabine) in cultured SW1573 cells. Int. J. Cancer, 1995, 62, 627-630.
71. Wiedemann, G.J.; d'Oleire, F.; Knop, E.; Eleftheriadis, S.; Bucsky, P.; Feddersen, S.; Kiouche, M.; Geisler, J.; Mentzel, M.; Schmucker, P.; Feyerabend, T.; Weiss, C.; Wagner, T. Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma. Cancer Res., 1994, 54, 5346-5350.
72. Hildebrandt, B.; Loeffel, J.; Deja, M.; Kerner, T.; Rick, O.; Bech-stein, W.; Von Ardenne, A.; Gerlach, H.; Siegert, W.; Wust, P.; Felix, R.; Huhn, D.; Riess, H. Whole body hyperthermia induces a renewed remission in a patient with refractory germ cell tumor after high-dose chemotherapy. Ann. Hematol., 1998, 77(Suppl. 72):222.
73. Hettinga, J.V.; Konings, A.W.; Kampinga, H.H. Reduction of cellular cisplatin resistance by hyperthermia--a review. Int. J. Hyperthermia, 1997, 13, 439-457.
74. Kampinga, H.H.; Dikomey, E. Hyperthermic radiosensitization: mode of action and clinical relevance. Int. J. Radiat. Biol., 2001, 77, 399-408.
75. Hunt, C.R.; Pandita, R.K.; Laszlo, A.; Higashikubo, R.; Agarwal, M.; Kitamura, T.; Gupta, A.; Rief, N.; Horikoshi, N.; Baskaran, R.; Lee, J.H.; Lobrich, M.; Paull, T.T.; Roti Roti, J.L.; Pandita, T.K. Hyperthermia activates a subset of ataxia-telangiectasia mutated effectors independent of DNA strand breaks and heat shock protein 70 status. Cancer Res., 2007, 67, 3010-3017.
76. Hurt, C.R.; Dix, D.J.; G.G., S. Genomic instability and enhanced radiosensitivity in Hsp70.1- and Hsp70.3-deficient mice. Mol. Cell. Biol., 2004, 24, 899-911.
77. Miller, R.C.; Roizin-Towle, L.; Komatsu, K.; Richards, M.; Hall, E.J. Interaction of heat with X-rays and cis-platinum; cell lethality and oncogenic transformation. Int. J. Hyperthermia, 1989, 5, 697-705.
78. Lee Wust; Seebass Nadobny; Felix Hynynen; Stauffer Diederich; Seegenschmiedt Roos; Sorbe Waterman. Physical Principles and Engineering. Spinger, 1995.
79. Hynynen, K.; Roemer, R.; Anhalt, D.; Johnson, C.; Xu, Z.X.; Swindell, W.; Cetas, T. A scanned, focused, multiple transducer ultrasonic system for localized hyperthermia treatments. Int. J. Hyperthermia, 1987, 3, 21-35.
80. Stauffer, P.R. Evolving technology for thermal therapy of cancer. Int. J. Hyperthermia, 2005, 21, 731-744.
81. D'Ambrosio, V.; Dughiero, F. Numerical model for RF capacitive regional deep hyperthermia in pelvic tumors. Med. Biol. Eng. Comput., 2007, 45, 459-466.
82. Johnson, J.E.; Neuman, D.G.; Maccarini, P.F.; Juang, T.; Stauffer, P.R.; Turner, P. Evaluation of a dual-arm Archimedean spiral array for microwave hyperthermia. Int. J. Hyperthermia, 2006, 22, 475-490.
83. Fatehi, D. Technical Quality of deep hyperthermia using the BSD-2000. Erasmus University Rotterdam, 2007.
84. Wust, P.; Cho, C.H.; Hildebrandt, B.; Gellermann, J. Thermal monitoring: invasive, minimal-invasive and non-invasive approaches. Int. J. Hyperthermia, 2006, 22, 255-262.
85. Bowman, R.R. A Probe for measuring temperature in radio-frequency-heated material. IEEE Transactions on Microwave Theory and Techniques, 1976, 24, 43-45.
86. Bolomey Bihan, L. Mizushina. Recent trends in noninvasive thermal control, Spinger, 1995
87. Gellermann, J.; Wlodarczyk, W.; Feussner, A.; Fahling, H.; Nadobny, J.; Hildebrandt, B.; Felix, R.; Wust, P. Methods and potentials of magnetic resonance imaging for monitoring radiofrequency hyperthermia in a hybrid system. Int. J. Hyperthermia, 2005, 21, 497-513.
88. Gellermann, J.; Wlodarczyk, W.; Ganter, H.; Nadobny, J.; Fahling, H.; Seebass, M.; Felix, R.; Wust, P. A practical approach to thermography in a hyperthermia/magnetic resonance hybrid system: validation in a heterogeneous phantom. Int. J. Radiat. Oncol. Biol. Phys., 2005, 61, 267-277.
89. Zitvogel, L.; Tesniere, A.; Kroemer, G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol., 2006, 6, 715-727.
90. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol., 2004, 22, 329-360.
91. Smyth, M.J.; Dunn, G.P.; Schreiber, R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol., 2006, 90, 1-50.
92. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 2004, 21, 137-148.
93. Sun, T.; Zhou, Y.; Li, H.; Han, X.; Shi, Y.; Wang, L.; Miao, X.; Tan, W.; Zhao, D.; Zhang, X.; Guo, Y.; Lin, D. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J. Exp. Med., 2005, 202, 967-974.
94. Gattinoni, L.; Powell, D.J., Jr.; Rosenberg, S.A.; Restifo, N.P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol., 2006, 6, 383-393.
95. Pages, F.; Galon, J.; Karaschuk, G.; Dudziak, D.; Camus, M.; Lazar, V.; Camilleri-Broet, S.; Lagorce-Pages, C.; Lebel-Binay, S.; Laux, G.; Fridman, W.H.; Henglein, B. Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood, 2005, 105, 1632-1639.
96. Kobayashi, N. Malignant neoplasms in registered cases of primary immunodeficiency syndrome. Jpn. J. Clin. Oncol., 1985, 15 Suppl 1, 307-312.
97. Nakachi, K.; Hayashi, T.; Imai, K.; Kusunoki, Y. Perspectives on cancer immuno-epidemiology. Cancer Sci., 2004, 95, 921-929.
98. Imai, K.; Matsuyama, S.; Miyake, S.; Suga, K.; Nakachi, K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet, 2000, 356, 1795-1799.
99. Curiel, T.J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mottram, P.; Evdemon-Hogan, M.; Conejo-Garcia, J.R.; Zhang, L.; Burow, M.; Zhu, Y.; Wei, S.; Kryczek, I.; Daniel, B.; Gordon, A.; Myers, L.; Lackner, A.; Disis, M.L.; Knutson, K.L.; Chen, L.; Zou, W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med., 2004, 10, 942-949.
100. Viguier, M.; Lemaitre, F.; Verola, O.; Cho, M.S.; Gorochov, G.; Dubertret, L.; Bachelez, H.; Kourilsky, P.; Ferradini, L. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol., 2004, 173, 1444-1453.
101. Bronte, V.; Kasic, T.; Gri, G.; Gallana, K.; Borsellino, G.; Marigo, I.; Battistini, L.; Iafrate, M.; Prayer-Galetti, T.; Pagano, F.; Viola, A. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med., 2005, 201, 1257-1268.
102. Morgan, W.F. Non-targeted and delayed effects of exposure to ionizing radiation: I. Radiation-induced genomic instability and bystander effects in vitro. Radiat. Res., 2003, 159, 567-580.
103. Prise, K.M.; Schettino, G.; Folkard, M.; Held, K.D. New insights on cell death from radiation exposure. Lancet Oncol., 2005, 6, 520-528.
104. Little, J.B. Cellular radiation effects and the bystander response. Mutat. Res., 2006, 597, 113-118.
105. Mole, R.H. Whole body irradiation; radiobiology or medicine? B r. J. Radiol., 1953, 26, 234-241.
106. Demaria, S.; Ng, B.; Devitt, M.L.; Babb, J.S.; Kawashima, N.; Liebes, L.; Formenti, S.C. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys., 2004, 58, 862-870.
107. Apetoh, L.; Tesniere, A.; Ghiringhelli, F.; Kroemer, G.; Zitvogel, L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res., 2008, 68, 4026-4030.
108. Green, D.R.; Ferguson, T.; Zitvogel, L.; Kroemer, G. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol., 2009, 9, 353-363.
109. Voll, R.E.; Herrmann, M.; Roth, E.A.; Stach, C.; Kalden, J.R.; Girkontaite, I. Immunosuppressive effects of apoptotic cells. Nature, 1997, 390, 350-351.
110. Matzinger, P. The danger model: a renewed sense of self. Science, 2002, 296, 301-305.
111. Kono, H.; Rock, K.L. How dying cells alert the immune system to danger. Nat. Rev. Immunol., 2008, 8, 279-289.
112. Gardella, S.; Andrei, C.; Ferrera, D.; Lotti, L.V.; Torrisi, M.R.; Bianchi, M.E.; Rubartelli, A. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep., 2002, 3, 995-1001.
113. Scaffidi, P.; Misteli, T.; Bianchi, M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature, 2002, 418, 191-195.
114. Campana, L.; Bosurgi, L.; Rovere-Querini, P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr. Opin. Immunol., 2008, 20, 518-523.
115. Bianchi, M.E.; Manfredi, A.A. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol. Rev., 2007, 220, 35-46.
116. Rovere-Querini, P.; Capobianco, A.; Scaffidi, P.; Valentinis, B.; Catalanotti, F.; Giazzon, M.; Dumitriu, I.E.; Muller, S.; Iannacone, M.; Traversari, C.; Bianchi, M.E.; Manfredi, A.A. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep., 2004, 5, 825-830.
117. Messmer, D.; Yang, H.; Telusma, G.; Knoll, F.; Li, J.; Messmer, B.; Tracey, K.J.; Chiorazzi, N. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol., 2004, 173, 307-313.
118. Dong Xda, E.; Ito, N.; Lotze, M.T.; Demarco, R.A.; Popovic, P.; Shand, S.H.; Watkins, S.; Winikoff, S.; Brown, C.K.; Bartlett, D.L.; Zeh, H.J., 3rd. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J. Immunother., 2007, 30, 596-606.
119. Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Criollo, A.; Ortiz, C.; Lidereau, R.; Mariette, C.; Chaput, N.; Mira, J.P.; Delaloge, S.; Andre, F.; Tursz, T.; Kroemer, G.; Zitvogel, L. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev., 2007, 220, 47-59.
120. Multhoff, G.; Botzler, C.; Wiesnet, M.; Muller, E.; Meier, T.; Wilmanns, W.; Issels, R.D. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int. J. Cancer, 1995, 61, 272-279.
121. Chen, T.; Guo, J.; Han, C.; Yang, M.; Cao, X. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J. Immunol., 2009, 182, 1449-1459.
122. Srivastava, P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol., 2002, 20, 395-425.
123. Melcher, A.; Todryk, S.; Hardwick, N.; Ford, M.; Jacobson, M.; Vile, R.G. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med., 1998, 4, 581-587.
124. Basu, S.; Binder, R.J.; Suto, R.; Anderson, K.M.; Srivastava, P.K. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol., 2000, 12, 1539-1546.
125. Noessner, E.; Gastpar, R.; Milani, V.; Brandl, A.; Hutzler, P.J.; Kuppner, M.C.; Roos, M.; Kremmer, E.; Asea, A.; Calderwood, S.K.; Issels, R.D. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J. Immunol., 2002, 169, 5424-5432.
126. Sauter, B.; Albert, M.L.; Francisco, L.; Larsson, M.; Somersan, S.; Bhardwaj, N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med., 2000, 191, 423-434.
127. Milani, V.; Noessner, E.; Ghose, S.; Kuppner, M.; Ahrens, B.; Scharner, A.; Gastpar, R.; Issels, R.D. Heat shock protein 70: role in antigen presentation and immune stimulation. Int. J. Hyperthermia, 2002, 18, 563-575.
128. Gastpar, R.; Gross, C.; Rossbacher, L.; Ellwart, J.; Riegger, J.; Multhoff, G. The cell surface-localized heat shock protein 70 epitope TKD induces migration and cytolytic activity selectively in human NK cells. J. Immunol., 2004, 172, 972-980.
129. Multhoff, G.; Botzler, C.; Jennen, L.; Schmidt, J.; Ellwart, J.; Issels, R. Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J. Immunol., 1997, 158, 4341-4350.
130. Burd, R.; Dziedzic, T.S.; Xu, Y.; Caligiuri, M.A.; Subjeck, J.R.; Repasky, E.A. Tumor cell apoptosis, lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever-like) whole body hyperthermia. J. Cell Physiol., 1998, 177, 137-147.
131. Shen, R.N.; Lu, L.; Young, P.; Shidnia, H.; Hornback, N.B.; Broxmeyer, H.E. Influence of elevated temperature on natural killer cell activity, lymphokine-activated killer cell activity and lectin-dependent cytotoxicity of human umbilical cord blood and adult blood cells. Int. J. Radiat. Oncol. Biol. Phys., 1994, 29, 821-826.
132. Dayanc, B.E.; Beachy, S.H.; Ostberg, J.R.; Repasky, E.A. Dissecting the role of hyperthermia in natural killer cell mediated anti-tumor responses. Int. J. Hyperthermia, 2008, 24, 41-56.
133. Mukhopadhaya, A.; Mendecki, J.; Dong, X.; Liu, L.; Kalnicki, S.; Garg, M.; Alfieri, A.; Guha, C. Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity. Cancer Res., 2007, 67, 7798-7806.
134. Shi, Y.; Evans, J.E.; Rock, K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature, 2003, 425, 516-521.
135. Martins, I.; Tesniere, A.; Kepp, O.; Michaud, M.; Schlemmer, F.; Senovilla, L.; Seror, C.; Metivier, D.; Perfettini, J.L.; Zitvogel, L.; Kroemer, G. Chemotherapy induces ATP release from tumor cells. Cell Cycle, 2009, 8, 3723-3728.
136. Miyoshi, N.; Watanabe, E.; Osawa, T.; Okuhira, M.; Murata, Y.; Ohshima, H.; Nakamura, Y. ATP depletion alters the mode of cell death induced by benzyl isothiocyanate. Biochim. Biophys. Acta., 2008, 1782, 566-573.
137. Berd, D.; Mastrangelo, M.J. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res., 1987, 47, 3317-3321.
138. Ghiringhelli, F.; Menard, C.; Puig, P.E.; Ladoire, S.; Roux, S.; Martin, F.; Solary, E.; Le Cesne, A.; Zitvogel, L.; Chauffert, B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother., 2007, 56, 641-648.
139. Obeid, M.; Tesniere, A.; Ghiringhelli, F.; Fimia, G.M.; Apetoh, L.; Perfettini, J.L.; Castedo, M.; Mignot, G.; Panaretakis, T.; Casares, N.; Metivier, D.; Larochette, N.; van Endert, P.; Ciccosanti, F.; Piacentini, M.; Zitvogel, L.; Kroemer, G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med., 2007, 13, 54-61.
140. van der Zee, J.; Gonzalez Gonzalez, D.; van Rhoon, G.C.; van Dijk, J.D.; van Putten, W.L.; Hart, A.A. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch deep hyperthermia group. Lancet, 2000, 355, 1119-1125.
141. Franckena, M.; Stalpers, L.J.; Koper, P.C.; Wiggenraad, R.G.; Hoogenraad, W.J.; van Dijk, J.D.; Warlam-Rodenhuis, C.C.; Jobsen, J.J.; van Rhoon, G.C.; van der Zee, J. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int. J. Radiat. Oncol. Biol. Phys., 2008, 70, 1176-1182.
142. Harima, Y.; Nagata, K.; Harima, K.; Ostapenko, V.V.; Tanaka, Y.; Sawada, S. A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma. Int. J. Hyperthermia, 2001, 17, 97-105.
143. Colombo, R.; Salonia, A.; Da Pozzo, L.F.; Naspro, R.; Freschi, M.; Paroni, R.; Pavone-Macaluso, M.; Rigatti, P. Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience. Crit. Rev. Oncol. Hematol., 2003, 47, 127-139.
144. Datta, N.R.B.; Kapoor, H.K. Thermoradiotherapy in the management of carcinoma cervix (stage IIIB): A controlled clinical study. Indian Med. Gaz., 1987, 121, 68-71.
145. Datta, N.R.; Bose, A.K.; Kapoor, H.K.; Gupta, S. Head and neck cancers: results of thermoradiotherapy versus radiotherapy. Int. J. Hyperthermia, 1990, 6, 479-486.
146. Kouloulias, V.; Plataniotis, G.; Kouvaris, J.; Dardoufas, C.; Gennatas, C.; Uzunoglu, N.; Papavasiliou, C.; Vlahos, L. Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial. Am. J. Clin. Oncol., 2005, 28, 91-99.
147. Sugimachi, K.; Kitamura, K.; Baba, K.; Ikebe, M.; Morita, M.; Matsuda, H.; Kuwano, H. Hyperthermia combined with chemotherapy and irradiation for patients with carcinoma of the oesophagus--a prospective randomized trial. Int. J. Hyperthermia, 1992, 8, 289-295.
148. Overgaard, J.; Gonzalez Gonzalez, D.; Hulshof, M.C.; Arcangeli, G.; Dahl, O.; Mella, O.; Bentzen, S.M. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet, 1995, 345, 540-543.
149. Jones, E.L.; Oleson, J.R.; Prosnitz, L.R.; Samulski, T.V.; Vujaskovic, Z.; Yu, D.; Sanders, L.L.; Dewhirst, M.W. Randomized trial of hyperthermia and radiation for superficial tumors. J. Clin. Oncol., 2005, 23, 3079-3085.
150. Vernon, C.C.; Hand, J.W.; Field, S.B.; Machin, D.; Whaley, J.B.; van der Zee, J.; van Putten, W.L.; van Rhoon, G.C.; van Dijk, J.D.; Gonzalez Gonzalez, D.; Liu, F.F.; Goodman, P.; Sherar, M. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int. J. Radiat. Oncol. Biol. Phys., 1996, 35, 731-744.
151. Wittlinger, M.; Rodel, C.M.; Weiss, C.; Krause, S.F.; Kuhn, R.; Fietkau, R.; Sauer, R.; Ott, O.J. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother. Oncol., 2009, 93, 358-363.
152. Wessalowski, R.; Van Heek-Romanowski, R.; Issels, R.D.; Jurgens, H.T.; Gobel, U. Estimated number of children with cancer eligible for hyperthermia based on population- and treatment-related criteria. Int. J. Hyperthermia, 1999, 15, 455-466.
153. Debes, A.; Oerding, M.; Willers, R.; Gobel, U.; Wessalowski, R. Sensitization of human Ewing's tumor cells to chemotherapy and heat treatment by the bioflavonoid quercetin. Anticancer Res., 2003, 23, 3359-3366.
154. Wessalowski, R.; Schneider, D.T.; Mils, O.; Hannen, M.; Calaminus, G.; Engelbrecht, V.; Pape, H.; Willers, R.; Engert, J.; Harms, D.; Gobel, U. An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin. Padiatr., 2003, 215, 303-309.
155. Thrall, D.E.; LaRue, S.M.; Yu, D.; Samulski, T.; Sanders, L.; Case, B.; Rosner, G.; Azuma, C.; Poulson, J.; Pruitt, A.F.; Stanley, W.; Hauck, M.L.; Williams, L.; Hess, P.; Dewhirst, M.W. Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy. Clin. Cancer Res., 2005, 11, 5206-5214.
156. Fatehi, D.; van der Zee, J.; de Bruijne, M.; Franckena, M.; van Rhoon, G.C. RF-power and temperature data analysis of 444 patients with primary cervical cancer: deep hyperthermia using the Sigma-60 applicator is reproducible. Int. J. Hyperthermia, 2007, 23, 623-643.
157. Berdov, B.A.; Menteshashvili, G.Z. Thermoradiotherapy of patients with locally advanced carcinoma of the rectum. Int. J. Hyperthermia, 1990, 6, 881-890.
158. Rau, B.; Wust, P.; Schlag, P.M. Stellenwert der Hyperthermie für die chirurgische Onkologie. Viszeralchirurgie, 2002, 37, 379-384
159. Schulze, T.; Wust, P.; Gellermann, J.; Hildebrandt, B.; Riess, H.; Felix, R.; Rau, B. Influence of neoadjuvant radiochemotherapy combined with hyperthermia on the quality of life in rectum cancer patients. Int. J. Hyperthermia, 2006, 22, 301-318.
160. De Haas-Kock, D.F.; Buijsen, J.; Pijls-Johannesma, M.; Lutgens, L.; Lammering, G.; van Mastrigt, G.A.; De Ruysscher, D.K.; Lambin, P.; van der Zee J. Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer. Cochrane Database Syst. Rev., 2009, CD006269.
161. Sharma, S.; Singhal, S.; Sandhu, A.P.S.; Ghoshal, S.; Gupta, B.D.; Yadav, N.S. Local thermo-radiotherapy in carcinoma cervix: Improved local control versus increased incidence of distant metastasis. Asia Oceania J. Obstet. Gynaecol. 1991, 17, 5-12.
162. Chen, H.W.; J-JF; Wei, L.A. A randomized trial of hyperthermo-radiochemotherapy for uterine cervix cancer. Chin. J. Clin. Oncol., 1997, 24, 249-251.
163. Issels, R.D.; Lindner, L.H.; Wust, P.; Hohenberger, P.; Jauch, K.; Daugaard, S.; Mansmann, U.; Hiddemann, W.; Blay, J.; Verweij, J. Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: a phase III randomized prospective trial (EORTC-ESHO Intergroup trial). J. Clin. Oncol. 2007, 25, 547.
164. Issels, R.L. L.H.; Wendtner, C.M.; Hohenberger, P.; Reichardt, P.; Daugaard, S.; Mansmann, U.; Hiddemann, W.; Blay, J.Y.; Verweij, J. Impact of regional hyperthermia (RHT) on response to neo-adjuvant chemotherapy and survival of patients with high-risk soft-tissue sarcoma (HR-STS): Results of the randomized EORTC-ESHO intergroup trial (NCI-00003052). Eur. J. Cancer Suppl., 2009, 7, 2-2.
165. Issels, R., Lindner, L.H., Verweij, J., Wust, P., Reichardt, P., Schem, B.C., Abdel-Rahman, S., Daugaard, S., Salat, C., Wendtner, C.M., Vujaskovic, Z., Wessalowski, R., Jauch, K.W., Dürr, H.R., Ploner, F., Baur-Melnyk, B., Mansmann, U., Hiddemann, W., Blay, J.Y., Hohenberger, P. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol., 2010.
166. Verwaal, V.J.; van Ruth, S.; de Bree, E.; van Sloothen, G.W.; van Tinteren, H.; Boot, H.; Zoetmulder, F.A. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol., 2003, 21, 3737-3743.
167. Eggermont, A.M.; de Wilt, J.H.; ten Hagen, T.L. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol., 2003, 4, 429-437